Oclacitinib maleate NEW
| Price | $33 | $46 | $72 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Oclacitinib maleate | CAS No.: 1640292-55-2 |
| Purity: 99.17% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Oclacitinib maleate |
| Description | Oclacitinib maleate (PF-03394197 maleate) is a novel inhibitor of JAK family members, with IC50 values ranging from 10 to 99 nM, and JAK1-dependent cytokines, with IC50 ranging from 36 to 249 nM, while not inhibiting a panel of 38 non-JAK kinases. |
| In vitro | Oclacitinib inhibits JAK family members by 50% at concentrations ranging from 10 to 99 nM and does not inhibit a panel of 38 non-JAK kinases. Oclacitinib is most potent at inhibiting JAK1. Oclacitinib also inhibits the function of JAK1-dependent cytokines involved in allergy and inflammation as well as pruritus. Oclacitinib has minimal effects on cytokines which does not activate the JAK1 enzyme in cells[1]. |
| In vivo | Oclacitinib administered orally at a dose of 0.4–0.6 mg/kg twice daily is safe and efficacious in controlling the pruritus associated with allergic dermatitis. Oclacitinib provides itch relief within 24 h that persistes through the treatment period, with over 70% of the treated dogs achieving a >50% reduction in pruritus by day 7[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 15 mg/mL (33.1 mM) Ethanol : 83 mg/mL (183 mM) DMSO : 83 mg/mL (183 mM) |
| Keywords | Oclacitinib | PF 03394197 | PF-03394197 Maleate | Oclacitinib maleate | inhibit | PF03394197 Maleate | PF03394197 | Oclacitinib Maleate | Inhibitor | PF 03394197 Maleate | Janus kinase | JAK |
| Inhibitors Related | Delgocitinib | Deucravacitinib | Ruxolitinib | Tofacitinib Citrate | Ibrutinib | Ruxolitinib phosphate | Gefitinib |
| Related Compound Libraries | Bioactive Compound Library | EMA Approved Drug Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Drug Repurposing Compound Library | Inhibitor Library | FDA-Approved Kinase Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $15.00/1Kg/Bag |
VIP4Y
|
XI'AN TIANGUANGYUAN BIOTECH CO., LTD.
|
2023-06-15 | |
| $10.00/1kg |
Nantong Guangyuan Chemicl Co,Ltd
|
2023-12-15 | ||
| $8.00/1kg |
VIP1Y
|
Henan Fengda Chemical Co., Ltd
|
2024-03-28 | |
| $0.00/1kg |
Hpets Biotech Company (Chongqing) Co.,ltd
|
2023-03-21 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY